L230 [L2-30] (ATCC® HB-8448)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  / 

Permits and Restrictions

View Restrictions

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Strain

Strain: ? (B cell); BALB/c (myeloma)

Applications
The antibody reacts with the M-23 antigen system.
Genes Expressed
immunoglobulin; monoclonal antibody; against a human melanoma cell line (M-23 antigen system)
Cellular Products
immunoglobulin; monoclonal antibody; against a human melanoma cell line (M-23 antigen system)
Comments
Animals were immunized with the SK-MEL-33 human melanoma cell line.
The antibody precipitates two glycoproteins (90000 and 150000 daltons)from extracts of SK-MEL-19 cells.
It reacted with all melanoma cell lines tested (n = 20), fetal and adult cultured melanocytes and various normal and neoplastic tissues.
The antibody reacts with the M-23 antigen system.
Complete Growth Medium RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM sodium pyruvate supplemented with 0.1 mM nonessential amino acids, 90%; fetal bovine serum, 10%
Subculturing
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Cryopreservation
culture medium 95%; DMSO, 5%
Isotype IgG1; kappa light chain
Basic Documentation
Restrictions

The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.

References

Houghton AN, et al. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 156: 1755-1766, 1982. PubMed: 7175440

Real FX, et al. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res. 45: 4401-4411, 1985. PubMed: 4028024

Cairncross JG, et al. Monoclonal antibodies against melanocytes. US Patent 4,806,628 dated Feb 21 1989

Oettgen HF, et al. Monoclonal antibodies to cell surface antigens of human malignant melanoma. US Patent 4,808,704 dated Feb 28 1989